When was Dapiglutide discovered?

Dapiglutide's discovery date is not publicly disclosed; however, Viking Therapeutics initiated clinical development in the early 2020s. Preclinical research and IND preparation likely began 1–2 years prior. The exact timeline from initial synthesis to human trials follows the standard investigational framework of 2–4 years.

How many clinical trials is Dapiglutide in?

Dapiglutide has two active clinical trials registered with the FDA as of 2024. Both are Phase 2 studies evaluating safety, tolerability, and efficacy in human subjects. Trial specifics, including enrollment status and completion dates, are available on ClinicalTrials.gov.

Why hasn't Dapiglutide been approved yet?

Dapiglutide is investigational and has not completed Phase 2 or Phase 3 clinical development. Regulatory approval requires successful pivotal trials, safety data across larger populations, manufacturing validation, and FDA/EMA review—a process typically taking 8–10 years from IND to market authorization.

Is Dapiglutide available for purchase or use outside clinical trials?

No. Dapiglutide is investigational and available only within registered clinical trials. It is not approved for prescription, and no legal commercial supply chain exists. Any claims of availability outside clinical studies should be treated with extreme caution.

How does Dapiglutide compare to approved GLP-1 drugs like semaglutide?

Dapiglutide is investigational; semaglutide (Ozempic, Wegovy) is FDA-approved and widely prescribed. Dapiglutide's efficacy and safety relative to approved agents remain unknown pending Phase 3 trial results. Direct comparison requires completed clinical data, not yet published.

Dapiglutide Regulatory History & Development Timeline

Dapiglutide is an investigational glucagon-like peptide-1 (GLP-1) receptor agonist currently under development by Viking Therapeutics. Unlike approved GLP-1 compounds already on the market, dapiglutide remains in early-stage clinical evaluation with two active trials in the United States. The compound represents a novel approach within the GLP-1 class, designed to explore potential metabolic effects in human subjects. As of 2024, dapiglutide has not received approval from the FDA, EMA, or Health Canada, and all therapeutic claims remain investigational pending clinical validation.

Discovery and Early Development

Dapiglutide emerged from Viking Therapeutics' research pipeline focused on metabolic and cardiovascular therapies. The compound was designed as a selective GLP-1 receptor agonist with a potential differentiated profile compared to existing approved agents like semaglutide and tirzepatide. Animal and preclinical studies conducted during the discovery phase suggested potential metabolic activity, laying the foundation for progression to human trials.

The development timeline reflects the standard investigational pathway: preclinical characterization of the compound's mechanism, formulation development, and manufacturing scale-up in preparation for Investigational New Drug (IND) application to regulatory authorities.

IND Application and First-in-Human Studies

Dapiglutide's regulatory history officially entered the public domain when Viking Therapeutics initiated clinical development. The company filed an IND application with the FDA to conduct human studies, a mandatory regulatory gatekeeping step in the United States. First-in-human (Phase 1) trials typically assess safety, tolerability, and pharmacokinetic properties before dose escalation in patient populations.

Research compounds in the GLP-1 class—such as ARA-290 and Alexamorelin—have followed similar developmental arcs, progressing from preclinical validation to early clinical safety assessments. Dapiglutide's regulatory pathway aligns with this broader investigational framework within the peptide space.

Phase 2 Clinical Trial Program

Dapiglutide currently has two active clinical trials registered with the FDA, indicating progression into proof-of-concept and dose-finding studies. A Phase 2a trial was registered to evaluate dapiglutide in subjects with type 2 diabetes, a population where GLP-1 agonists have demonstrated well-established clinical benefit with approved agents. This trial design typically enrolls 50–200 participants and runs for 12–16 weeks, allowing researchers to assess efficacy signals, optimal dosing, and adverse event profiles.

The second active trial represents continued clinical exploration, though specific enrollment targets and primary endpoints align with Viking's broader development strategy. Research indicates GLP-1 receptor agonists produce metabolic effects through multiple pathways, and dapiglutide's trials are designed to characterize its unique contribution to this pharmacological class.

Regulatory Classification and Approval Status

As of 2024, dapiglutide holds the classification of investigational across all major regulatory jurisdictions:

FDA (United States): Not approved; currently in IND status under active clinical investigation
EMA (European Union): Not authorised; no Marketing Authorisation Application (MAA) filed
Health Canada: Not approved; no New Drug Submission (NDS) filed

This regulatory status is consistent with many emerging peptide therapeutics. For comparison, Abaloparatide, a parathyroid hormone-related peptide agonist, required multiple Phase 3 trials and years of regulatory review before achieving FDA approval in 2017. Dapiglutide's timeline suggests it remains in an earlier stage of development.

Comparative Regulatory Timeline

Understanding dapiglutide's progress requires context. Approved GLP-1 agonists like exenatide (2005) and liraglutide (2010) took 8–10 years from discovery to initial FDA approval. A comprehensive analysis of GLP-1 development timelines shows typical progression: IND (Year 1–2) → Phase 1 (Year 2–3) → Phase 2 (Year 3–5) → Phase 3 (Year 5–8) → BLA/NDA review (Year 8–10). Dapiglutide's current position—two active Phase 2 trials—places it approximately 3–4 years into this expected trajectory if approved timelines hold.

Other investigational peptides like 5-Amino-1MQ and compounds in similar metabolic indications follow comparable regulatory arcs, with significant time and investment required between proof-of-concept and market authorization.

Clinical Trial Data and Study Design

Publicly available trial registrations indicate dapiglutide's Phase 2 program uses glucose control and body weight as primary endpoints, standard measures for GLP-1 efficacy assessment. These endpoints reflect regulatory guidance from the FDA's 2022 guidance on antidiabetic drugs, which requires demonstration of glycaemic control and cardiovascular or weight benefits in certain populations.

The dual-trial structure suggests Viking is pursuing both population diversity and dose optimization—a typical strategy to support future Phase 3 pivotal trial design. Research on GLP-1 pharmacodynamics demonstrates dose-response relationships across multiple metabolic parameters, informing the selection of doses for pivotal efficacy studies.

Manufacturing and Regulatory Quality Considerations

Parallel to clinical development, dapiglutide's regulatory pathway includes manufacturing oversight. Peptide drugs require stringent quality control and analytical methods per FDA guidance on peptide drug products. Dapiglutide, as a synthetic peptide agonist, must demonstrate consistent manufacturing purity, potency, and stability to support clinical and eventual commercial supply.

This requirement mirrors the experience of approved peptide therapeutics like Abarelix, a GnRH antagonist that required extensive pharmaceutical development before regulatory clearance.

Current Development Status and Future Milestones

As of mid-2024, dapiglutide remains investigational with no announced regulatory submissions or approval timelines disclosed by Viking Therapeutics. The company has not filed an NDA with the FDA or MAA with the EMA, indicating either ongoing Phase 2 enrollment or internal decision-making regarding Phase 3 planning.

Projected future milestones likely include:

Completion of Phase 2 trials (expected 2024–2025 based on trial timelines)
Phase 3 pivotal trial initiation (contingent on Phase 2 efficacy readouts)
FDA pre-BLA meeting (typically held 6–12 months before anticipated BLA submission)
NDA/BLA submission (estimated 2026–2028 if Phase 3 trials meet endpoints)
FDA review period (standard 10-month review; priority review possible if novel benefits demonstrated)

Regulatory Pathway Uncertainties

Dapiglutide's final regulatory pathway will depend on Phase 2 and Phase 3 data. If efficacy signals are robust and adverse event profiles favorable, Viking may pursue Accelerated Approval designation from the FDA—a pathway available for serious conditions where an unmet medical need exists. Type 2 diabetes management qualifies, though regulatory precedent suggests standard approval pathways are more typical for incremental GLP-1 advances.

Conversely, if dapiglutide's development encounters safety signals or fails to demonstrate differentiation from approved agents, the regulatory timeline may extend, pause, or the program may be deprioritized—a reality affecting many investigational compounds.

Implications for the Investigational Peptide Landscape

Dapiglutide's regulatory history reflects broader trends in peptide drug development. The GLP-1 class has become increasingly competitive, with both approved agents and numerous investigational candidates (including tirzepatide, retatrutide, and others) pursuing expanded indications. Regulatory submissions for GLP-1 compounds have increased significantly since 2015, creating a crowded development environment.

This context makes dapiglutide's differentiation strategy critical. Whether the compound offers unique benefits—faster onset, improved tolerability, or additional metabolic effects—will influence both regulatory reception and commercial viability post-approval.

Data Transparency and Regulatory Communication

Vikings Therapeutics has maintained selective communication regarding dapiglutide's development. Trial registrations on ClinicalTrials.gov provide transparency to the biomedical research community, though detailed efficacy and safety data remain confidential until peer-reviewed publication or regulatory submission. This standard regulatory practice protects intellectual property while ensuring public oversight of active human research.

Once dapiglutide files for regulatory approval (if it does), the company will be required to disclose comprehensive clinical and nonclinical data packages, including adverse event summaries, manufacturing details, and analytical methods—information publicly accessible via FDA databases for approved drugs.

Dapiglutide Regulatory History: From Discovery to Current Clinical Development